Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups
Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups
Hartmann, A. M.; Bastian, L.; Barz, M. J.; Haas, J.; Amelunxen, E.; Ehm, P.; Lenk, L.; Kotrova, M.; Beder, T.; Steffen, F.; Rauwolf, K.; Wolgast, N.; Bendig, S.; Bozzetti, C.; Alten, J.; Mondal, M.; Rademacher, A.; Heymann, J.; Walter, W.; Haferlach, C.; Ströh, A.-S.; Bergmann, A. K.; Burmeister, T.; Gökbuget, N.; Bornhauser, B.; Bourquin, J.-P.; Brüggemann, M.; Schrappe, M.; Cario, G.; Baldus, C. D.
AbstractKMT2A-rearranged B-cell acute lymphoblastic leukemia (KMT2Ar B-ALL) exhibits significant heterogeneity in age of onset, developmental origins, and clinical outcomes. The interplay of individual factors influencing early treatment response within this high-risk molecular subtype remains poorly elucidated. To identify determinants of early treatment response to induction chemotherapy, we analysed 465 KMT2Ar B-ALL cases spanning a wide age range (1 month to 89 years) by integrating transcriptomic and genomic profiling with functional drug response and measurable residual disease (MRD) kinetics. We observed a strong inverse correlation between MRD clearance with advancing age (p=2.1E-04), proximity to early B-cell-precursor developmental state (low maturity score, p=1.3E-03) and AFF1 as fusion partner (p=7.0E-04). A combined model confirmed the predominate impact of both maturity and KMT2A fusion partner on MRD response, supporting the concept that the cells developmental state defines therapy response. Gene expression analysis identified cellular traits that relate to MRD response (e.g. chromatin organization, immune modulation and proliferation). This gene expression classifier grouped cases by MRD response but also by ex-vivo induction chemotherapy sensitivity. Notably, good responders to ex-vivo induction chemotherapy were characterized by a higher maturity score (p=1.8E-03), whereas less mature KMT2Ar B-ALL cases ex-vivo drug response profiles showed higher Venetoclax sensitivity. This study provides an integrative framework of the biological determinants of treatment response and possible therapeutic implications in KMT2Ar B-ALL.